<?xml version="1.0" encoding="UTF-8"?>
<p>However, Malaria and leishmaniasis are still neglected diseases and have only recently attracted the attention of vaccine manufacturers. These diseases are not endemic in the USA, where the big vaccine industry and advanced technology are concentrated. However, geopolitics is also playing a role, and as happened in the colonies of the British Empire in the past, the interest of USA companies in producing anti-protozoa vaccines increased when American troops returned home with 
 <italic>Leishmania</italic> infections contracted in Middle East countries. In fact, there is also a specific support from the USA military forces in R&amp;D for vaccines that could protect their personnel from diseases that are endemic in areas of conflict (
 <xref rid="B32" ref-type="bibr">32</xref>). However, since preventive vaccines are commercially less profitable than drug development (
 <xref rid="B33" ref-type="bibr">33</xref>, 
 <xref rid="B34" ref-type="bibr">34</xref>) most American pharmaceutical companies have focused their research on immunotherapeutic formulations (
 <xref rid="B34" ref-type="bibr">34</xref>).
</p>
